Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma
Open Access
- 1 December 2019
- journal article
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 3 (4) , 485-494
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Role of PET in LymphomaCurrent Treatment Options in Oncology, 2014
- Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatmentWorld Journal of Gastroenterology, 2014
- Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphomaLeukemia & Lymphoma, 2013
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research NetworkBritish Journal of Cancer, 2011
- Use of antineoplastic agents in patients with cancer who have HIV/AIDSThe Lancet Oncology, 2011
- Racial differences in the presentation and outcomes of diffuse large B‐cell lymphoma in the United StatesCancer, 2010
- Hepatitis C in the rituximab eraBlood, 2010
- Highly increased familial risks for specific lymphoma subtypesBritish Journal of Haematology, 2009
- Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle PegfilgrastimThe Oncologist, 2007
- The role of FDG-PET scans in patients with lymphomaBlood, 2007